Association of overweight/obesity and overweight/obesity-related metabolic dysfunction-associated steatotic liver disease in young adults with coronary artery calcification later in life

被引:2
|
作者
Wang, Jia-Jie [1 ]
Zheng, Zhichao [1 ]
Zhang, Ying [1 ]
机构
[1] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Cardiol, 106 Zhongshan 2nd Rd, Guangzhou 510080, Peoples R China
来源
DIABETES OBESITY & METABOLISM | 2024年 / 26卷 / 09期
关键词
CAC; MASLD; obesity; overweight; CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; RISK DEVELOPMENT; UNITED-STATES; WEIGHT-LOSS; OBESITY; PREVALENCE; NUTRITION; ADOLESCENTS; MANAGEMENT;
D O I
10.1111/dom.15733
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimThe association of overweight/obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) in young adulthood with subclinical atherosclerosis [coronary artery calcification (CAC) and abdominal aortic calcification (AAC)] by middle age is unknown.MethodIn total, 2274 participants aged 28-39 years from the coronary artery risk development in young adults study at year 10 (1995-1996) who were re-examined 15 years later were included. CAC and AAC were measured at year 25 using computed tomography. We examined the utility of three young adult phenotypes (lean group; overweight/obese group; overweight/obese MASLD group) at year 10 in predicting CAC or AAC by middle age. Modified Poisson regression was used to estimate the association between groups and CAC, and AAC. Independent determinates of CAC and AAC were determined with linear regression models.ResultsCompared with individuals categorized as lean in young adulthood, the relative risk for CAC by middle age was 1.09 (95% confidence interval: 0.93-1.28) for those with overweight/obesity and 1.32 (95% confidence interval: 1.08-1.61) for those with overweight/obesity-related MASLD. For AAC, no difference was observed between these three groups. Group, systolic blood pressure and group x systolic blood pressure interaction were all the independent determinates for CAC.ConclusionIn this study, young adults with overweight/obesity-related MASLD have a higher risk of developing CAC by middle age. These abnormalities are only partially explained by traditional cardiovascular risk factors, and overweight/obesity-related MASLD has an independent impact on CAC. Our study provides evidence for identifying young adults at higher risk of developing subclinical atherosclerosis.
引用
收藏
页码:3860 / 3867
页数:8
相关论文
共 50 条
  • [41] Associations between circulating amino acids and metabolic dysfunction-associated steatotic liver disease in individuals living with severe obesity
    Maltais-Payette, Ina
    Bourgault, Jerome
    Gauthier, Marie-Frederique
    Biertho, Laurent
    Marceau, Simon
    Julien, Francois
    Mitchell, Patricia L.
    Couture, Christian
    Briere, Francis
    Corbeil, Jacques
    Arsenault, Benoit J.
    Tchernof, Andre
    PHYSIOLOGICAL REPORTS, 2025, 13 (03):
  • [42] Association between remnant cholesterol and metabolic dysfunction-associated steatotic liver disease in the elderly
    Lan, Yanqi
    Guo, Zhinan
    Dai, Junsheng
    Chen, Kailin
    Chen, Youlan
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (09) : 1557 - 1564
  • [43] Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity
    Hupa-Breier, Katharina L.
    Schenk, Heiko
    Campos-Murguia, Alejandro
    Wellhoener, Freya
    Heidrich, Benjamin
    Dywicki, Janine
    Hartleben, Bjoern
    Boeker, Clara
    Mall, Julian
    Terkamp, Christoph
    Wilkens, Ludwig
    Becker, Friedrich
    Rudolph, Karl Lenhard
    Manns, Michael Peter
    Mederacke, Young-Seon
    Marhenke, Silke
    Redeker, Hanna
    Lieber, Maren
    Iordanidis, Konstantinos
    Taubert, Richard
    Wedemeyer, Heiner
    Noyan, Fatih
    Hardtke-Wolenski, Matthias
    Jaeckel, Elmar
    MOLECULAR METABOLISM, 2025, 93
  • [44] Metabolic Dysfunction-Associated Steatotic Liver Disease in Severe Obesity and Concordance between Invasive (Biopsy) and Noninvasive (OWLiver®) Diagnoses
    Navarro-Masip, Elia
    Mestres Petit, Nuria
    Salinas-Roca, Blanca
    Herrerias, Fernando
    Vilardell, Felip
    de la Fuente, Mari Cruz
    Pallares, Judit
    Santamaria, Maite
    Zorzano-Martinez, Marta
    Sanchez, Enric
    Matias-Guiu, Xavier
    Lopez-Cano, Carolina
    Soler, Ana Gloria
    Leon-Mengibar, Josep
    Bueno, Marta
    Lecube, Albert
    OBESITY FACTS, 2024, 17 (05) : 473 - 482
  • [45] Recent advances in age-related metabolic dysfunction-associated steatotic liver disease
    He, Qian-Jun
    Li, Yi-Fei
    Zhao, Ling-Tong
    Lin, Chun-Tong
    Yu, Chun-Yan
    Wang, Dan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (07) : 652 - 662
  • [46] Erectile Dysfunction as an Obesity-Related Condition in Elderly Men with Coronary Artery Disease
    Biernikiewicz, Malgorzata
    Sobieszczanska, Malgorzata
    Szuster, Ewa
    Pawlikowska-Gorzelanczyk, Anna
    Janocha, Anna
    Rozek-Piechura, Krystyna
    Rusiecka, Agnieszka
    Gebala, Jana
    Okrzymowska, Paulina
    Kalka, Dariusz
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (07)
  • [47] Metabolic dysfunction-associated steatotic liver disease: ferroptosis related mechanisms and potential drugs
    Zhu, Baoqiang
    Wei, Yuankui
    Zhang, Mingming
    Yang, Shiyu
    Tong, Rongsheng
    Li, Wenyuan
    Long, Enwu
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [48] Late-Life Metabolic Dysfunction-Associated Steatotic Liver Disease and its Association With Physical Disability and Dementia
    Clayton-Chubb, Daniel
    Kemp, William W.
    Majeed, Ammar
    Woods, Robyn L.
    Ryan, Joanne
    Murray, Anne M.
    Chong, Trevor T. J.
    Lubel, John S.
    Tran, Cammie
    Hodge, Alexander D.
    Schneider, Hans G.
    Mcneil, John J.
    Roberts, Stuart K.
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2024, 79 (04):
  • [49] PARENTAL OBESITY AT PREGNANCY WITH RISK OF METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE IN YOUNG ADULT OFFSPRING
    Tica, Stefani
    Zong, Xiaoyu
    Tarr, Phillip I.
    Cao, Yin
    GASTROENTEROLOGY, 2024, 166 (05) : S26 - S27
  • [50] VALIDATION OF THE AGA AND AASLD CARE PATHWAYS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN A PROSPECTIVE COHORT OF OVERWEIGHT AND OBESE INDIVIDUALS
    Ajmera, Veeral
    Tincopa, Monica
    Tavaglione, Federica
    Bettencourt, Ricki
    Richards, Lisa
    Loomba, Rohit
    HEPATOLOGY, 2024, 80 : S584 - S585